Stocks Continue To See Considerable Strength After Early Rally – U.S. Commentary

Stocks Continue To See Considerable Strength After Early Rally – U.S. Commentary
After moving notably higher early in the session, stocks continue to see considerable strength in mid-day trading on Wednesday. With the upward move, the Dow has reached its best intraday level in almost a month. In recent trading, the major averages reached new highs for the session. The Dow is up 312.33 points or 1.2 percent at 25,947.34, the Nasdaq... Read More

Stocks Climb Firmly Into Positive Territory In Morning Trading – U.S. Commentary

Stocks Climb Firmly Into Positive Territory In Morning Trading – U.S. Commentary
Stocks have shown a strong move to the upside in morning trading on Wednesday, adding to the gains posted in the previous session. With the upward move, the Dow has reached its best intraday level in almost a month. Currently, the major averages are firmly in positive territory. The Dow is up 225.11 points or 0.9 percent at 25,860.12, the... Read More

MiMedx stock plunges after receiving delisting notice from Nasdaq

MiMedx stock plunges after receiving delisting notice from Nasdaq
Shares of MiMedx Group Inc. MDXG, -34.73% plummeted 34% to pace all Nasdaq losers in morning trade Wednesday, after the biopharmaceutical company disclosed that the Nasdaq will suspend trading in its stock starting Nov. 8, ahead of a delisting. The delisting notice comes as the company has failed to regain compliance with Securities and Exchange Commission reporting obligations amid an... Read More

Vericel Still Hot?

Vericel Still Hot?
Shares of Vericel Corporation (VCEL) have gained an impressive 200% year-to-date, way ahead of the mere 0.9% returned by iShares Nasdaq Biotechnology ETF (IBB) for the same period. Vericel, formerly known as Aastrom Biosciences Inc., is focused on developing advanced cell therapies for the sports medicine and severe burn care markets. The Company currently markets two FDA approved autologous cell... Read More

All’s Well With VCEL, Time To Keep MOR In Mind, MYL Pulls Off Surprise

All’s Well With VCEL, Time To Keep MOR In Mind, MYL Pulls Off Surprise
The following are some of today’s top gainers in the pharma/biotech sector. 1. Vericel Corp. (VCEL) Gained 44.28% to close Tuesday’s (Nov.6) trading at $16.65. News: The Company reported narrower loss on 58% revenue growth for the third quarter of 2018, and raised its full year revenue guidance. Net loss for the third quarter ended September 30, 2018 narrowed to... Read More

CLSD Loses Shine, AVDL’s Q3 Results Disappoint, CWBR Briefly Suspends NASH Trial

CLSD Loses Shine, AVDL’s Q3 Results Disappoint, CWBR Briefly Suspends NASH Trial
The following are some of the pharma/biotech stocks that posted the biggest percentage decline today. 1. Clearside Biomedical Inc. (CLSD) Lost 62.77% to close Monday’s (Nov.5) trading at $2.07. News: The Company’s phase III study of combination therapy in Retinal Vein Occlusion did not meet its primary endpoint. The study, dubbed SAPPHIRE, investigated the superiority of XIPERE used together with... Read More